Skip to content

First-Trimester Metabolic Dysfunction-Associated Steatotic Liver Disease and Risk of Hypertensive Disorders of Pregnancy: A Prospective Cohort Study.

Oct 2026 · Clinics And Research in Hepatology and Gastroenterology · Vol 50, pp. 102937 · 0 citations · 21 references
Medicine

TL;DR

Early-pregnancy MASLD was associated with higher odds of subsequent HDPs in this cohort, and the fully adjusted model did not demonstrate a statistically significant association, but the effect estimate was approximately threefold and was similar in the exploratory stepwise model.

Abstract

INTRODUCTION Metabolic-dysfunction-associated steatotic liver disease is the most common chronic liver condition globally, increasingly relevant in pregnancy due to rising maternal metabolic risks. The study explores MASLD in early pregnancy as a potential independent risk factor for hypertensive disorders of pregnancy (HDPs). METHODOLOGY In this prospective study, we assessed MASLD in 198 pregnant women at 10-14 weeks' gestation using demographic, clinical, metabolic, and hepatic parameters measured by transient elastography. We followed participants prospectively for the development of HDPs. We used standardised protocols, blinded operators, and validated cutoff values. We used multivariable logistic regression to assess the association between MASLD and HDPs, adjusting for prespecified clinical and metabolic covariates.

Results

MASLD was present in 48 (24.2%) women. HDPs developed in 11/48 (22.9%) women with MASLD compared with 9/150 (6.0%) without MASLD (p=0.002). In the fully adjusted model, MASLD was associated with higher odds of HDPs, although the association did not reach statistical significance (adjusted OR 2.89, 95% CI 0.90-9.54; p=0.075). In the exploratory bidirectional stepwise model, MASLD remained associated with HDPs (aOR 2.99, 95% CI 1.08-8.29; p=0.035).

Conclusion

MASLD was detected in 24% of women in early pregnancy. Early-pregnancy MASLD was associated with higher odds of subsequent HDPs in this cohort. Although the fully adjusted model did not demonstrate a statistically significant association, the effect estimate was approximately threefold and was similar in the exploratory stepwise model. Given the small number of HDPs events and the limitations of stepwise variable selection, these findings should be considered hypothesis-generating and require confirmation in larger prospective studies.

View source

Similar papers

Review Open access Nov 2026

Pregnancy and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Introduction . Metabolic dysfunction‑associated steatotic liver disease (MASLD) demonstrates a significant prevalence among women of reproductive age (approximately 10 %), yet the pathophysiological mechanisms of its impact on gestation remain insufficiently understood, and management algorithms for patients before,...

I. Gaisin, Ахметсалим Сабирович Галеев · 0 citations
Open access Sep 2026

FEATURES OF CARBOHYDRATE AND LIPID METABOLISM IN PREGNANT WOMEN WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE

Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnancy often has a latent course, complicating diagnosis. To evaluate the dynamics of carbohydrate and lipid metabolism parameters in pregnant women with MASLD in the II-III trimesters and compare it with the dynamics of non-invasive indicators of l...

A. B. Prylutska, Y. V. Salata, D. O. Govseev · 0 citations
Open access 2025

Screening for metabolic dysfunction-associated steatotic liver disease related advanced fibrosis in diabetology: a prospective multi-center study.

Objective: Screening for advanced fibrosis (AF) due to metabolic dysfunction-associated steatotic liver disease (MASLD) is recommended in diabetology. This study aimed to compare the performance of non-invasive tests (NITs) and 2-step algorithms for detecting patients with high-risk AF requiring referral to hepatologis...

C. Caussy, B. Vergès, Damien Leleu et al. · 0 citations
Nov 2026

Rising Prevalence of Metabolic Dysfunction - Associated Steatotic Liver Disease in an urban South Indian screening cohort: a Retrospective Cross-sectional Study.

Nearly two-thirds of asymptomatic urban South Indian adults screened met MASLD criteria, predominantly working-age individuals under-detected by conventional tools, suggesting FibroScan-based screening should be considered in preventive health programmes to enable earlier detection.

Balasubramanian Karuppasamy, D. Jothimani, H. Ramachandran et al. · 0 citations
Review Open access Oct 2026

Association between metabolic dysfunction-associated steatotic liver disease and atherosclerotic cardiovascular disease in a tertiary care hospital: A cross-sectional study

Obesity, diabetes, and metabolic syndrome are becoming increasingly prevalent in Saudi Arabia, and therefore, raising concerns about metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic steatohepatitis (MASH), and related cardiovascular complications. This study compared the occurrence of a...

Reem K. AlManea, Kossay El-Abd, Sara H. Alsinan et al. · 0 citations
Open access Oct 2026

Type 1 Diabetes Mellitus And Metabolic Dysfunction-Associated Steatotic Liver Disease In Children And Adolescents: A Cross-Sectional Study.

Adiposity-related parameters and dyslipidemia appear to be important clinical features associated with hepatic steatosis in pediatric T1DM, which had a higher prevalence of CAP-based hepatic steatosis/MASLD than healthy controls.

Hanife Ayşegül Arsoy, Ö. Kara, Murat Keskin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.